Lamivudine Dosage

Medically reviewed by Drugs.com. Last updated on Jun 27, 2023.

Usual Adult Dose for HIV Infection

150 mg orally twice a day or 300 mg orally once a day

Use: In combination with other antiretroviral agents, for the treatment of HIV-1 infection

Usual Adult Dose for Chronic Hepatitis B

100 mg orally once a day

Comments:

• HIV counseling and testing should be offered to all patients before starting treatment with this product and periodically during therapy due to risk of resistant HIV-1 emerging and limited treatment options if this product is prescribed to treat chronic HBV infection in a patient who has unrecognized HIV-1 infection or acquires HIV-1 infection during therapy.
• The optimal duration of therapy is not known.

Use: For the treatment of chronic HBV infection associated with evidence of hepatitis B viral replication and active liver inflammation

Usual Adult Dose for Nonoccupational Exposure

US CDC Recommendations:

• Weight less than 50 kg: 4 mg/kg orally twice a day
• Maximum dose: 150 mg/dose
• Weight at least 50 kg: 150 mg orally twice a day OR 300 mg orally once a day

Duration of therapy: 28 days

Comments:

• This drug and zidovudine plus (raltegravir or dolutegravir) is recommended as the preferred regimen for nonoccupational postexposure prophylaxis of HIV infection in adults with CrCl less than 60 mL/min; this drug and zidovudine plus darunavir/ritonavir is recommended as an alternative regimen for such patients. Dose should be adjusted to degree of renal function.
• If other alternatives are considered, this drug is recommended as a component in various regimens.
• Prophylaxis should be started as soon as possible, within 72 hours of exposure.
• Current guidelines should be consulted for additional information.

Usual Adult Dose for Occupational Exposure

US Public Health Service Working Group Recommendations:

• Preferred dose: 300 mg orally once a day
• Alternative dose: 150 mg orally twice a day

Duration of therapy: 28 days, if tolerated

Comments:

• Recommended as a component in alternative regimens for HIV postexposure prophylaxis
• Prophylaxis should be started as soon as possible, preferably within hours after exposure.
• The optimal duration of prophylaxis is unknown and may differ based on institution protocol.
• Current guidelines should be consulted for additional information.

Usual Pediatric Dose for HIV Infection

3 months or older:
Oral solution: 5 mg/kg orally twice a day OR 10 mg/kg orally once a day

• Maximum dose: 300 mg/day

Tablets:

• Weight 14 to less than 20 kg: 75 mg orally twice a day OR 150 mg orally once a day
• Weight 20 to less than 25 kg: 75 mg orally in the morning and 150 mg in the evening OR 225 mg orally once a day
• Weight at least 25 kg: 150 mg orally twice a day OR 300 mg orally once a day

Comments:

• For patients starting therapy with the oral solution, HIV-1 viral load and CD4+ cell count/percentage should be considered when selecting dosing interval.
• The scored tablet is the preferred formulation for HIV-1-infected patients weighing at least 14 kg who can safely and reliably swallow tablets; ability to swallow tablets should be assessed before the scored tablets are prescribed.
• In a clinical trial, pediatric patients who received lamivudine oral solution (at doses about 8 mg/kg/day) with other antiretroviral oral solutions had lower rates of virologic suppression, lower plasma lamivudine exposure, and developed viral resistance more often than those receiving lamivudine tablets.
• When possible, an all-tablet regimen should be used to avoid potential interaction with sorbitol.
• More frequent monitoring of HIV-1 viral load should be considered when treating with the oral solution.
• Tablets: Data regarding efficacy of once-daily dosing limited to patients who switched from twice-daily dosing to once-daily dosing after 36 weeks of therapy.

Use: In combination with other antiretroviral agents, for the treatment of HIV-1 infection

Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) Recommendations:
Oral Solution:

• Neonates (at least 32 weeks gestation at birth) and infants (birth to less than 4 weeks): 2 mg/kg orally twice a day
• Infants and children aged 4 weeks to less than 3 months: 4 mg/kg orally twice a day
• Infants and children aged 3 months to less than 3 years: 5 mg/kg orally twice a day
• Maximum dose: 150 mg/dose
• Children and adolescents aged 3 years or older: 5 mg/kg orally twice a day OR 10 mg/kg orally once a day
• Maximum dose: 300 mg/day

Tablets:

• Weight 14 to less than 20 kg: 75 mg orally twice a day OR 150 mg orally once a day
• Weight 20 to less than 25 kg: 75 mg orally in the morning and 150 mg in the evening OR 225 mg orally once a day
• Weight at least 25 kg: 150 mg orally twice a day OR 300 mg orally once a day

Comments:

• The Panel supports switching from twice-daily dosing to once-daily dosing of this drug in patients 3 years or older who have been clinically stable for 36 weeks with undetectable viral loads and stable CD4 T lymphocyte counts.
• Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Chronic Hepatitis B

2 to 17 years: 3 mg/kg orally once a day
Maximum dose: 100 mg/day

Comments:

• HIV counseling and testing should be offered to all patients before starting treatment with this product and periodically during therapy due to risk of resistant HIV-1 emerging and limited treatment options if this product is prescribed to treat chronic HBV infection in a patient who has unrecognized HIV-1 infection or acquires HIV-1 infection during therapy.
• The optimal duration of therapy is not known.

Use: For the treatment of chronic HBV infection associated with evidence of hepatitis B viral replication and active liver inflammation

Renal Dose Adjustments

HBV INFECTION:
Adults:

• CrCl 30 to 49 mL/min: 100 mg orally as first dose, then 50 mg orally once a day
• CrCl 15 to 29 mL/min: 100 mg orally as first dose, then 25 mg orally once a day
• CrCl 5 to 14 mL/min: 35 mg orally as first dose, then 15 mg orally once a day
• CrCl less than 5 mL/min: 35 mg orally as first dose, then 10 mg orally once a day

Pediatric Patients:

• Renal dysfunction: Insufficient data to recommend a specific dosage

HIV-1 INFECTION:
Adults and Adolescents (at least 25 kg):

• CrCl 30 to 49 mL/min: 150 mg orally once a day
• CrCl 15 to 29 mL/min: 150 mg orally as first dose, then 100 mg orally once a day
• CrCl 5 to 14 mL/min: 150 mg orally as first dose, then 50 mg orally once a day
• CrCl less than 5 mL/min: 50 mg orally as first dose, then 25 mg orally once a day

Pediatric Patients:

• Renal dysfunction: Insufficient data to recommend a specific dose adjustment; reduction in dose and/or increase in dosing interval should be considered.

Comments:

• HBV Infection: The 5 mg/mL oral solution should be used for doses below 100 mg.

Liver Dose Adjustments

Liver dysfunction: No adjustment recommended.

Comments:

• Safety and efficacy have not been established in patients with decompensated liver disease.

Precautions

US BOXED WARNINGS:

• EXACERBATIONS OF HEPATITIS B: Severe acute exacerbations of hepatitis B reported in patients with HBV (including those coinfected with HIV-1) after stopping this drug. Hepatic function of HBV-infected patients should be closely monitored with clinical and laboratory follow-up for at least several months after stopping this drug. If appropriate, initiation/resumption of antihepatitis B therapy may be necessary.
• IMPORTANT DIFFERENCES AMONG LAMIVUDINE-CONTAINING PRODUCTS: Epivir tablets and oral solution (used to treat HIV-1 infection) contain a higher dose of lamivudine than Epivir-HBV tablets and oral solution (used to treat chronic HBV infection). Only products appropriate for treatment of HIV-1 should be used in HIV-1-infected patients.
• RISK OF HIV-1 RESISTANCE WITH EPIVIR-HBV USE IN UNRECOGNIZED/UNTREATED HIV-1 INFECTION: Epivir-HBV is not approved for treatment of HIV-1 infection as the lamivudine dosage is subtherapeutic and monotherapy is inappropriate. HIV-1 resistance may develop in chronic HBV-infected patients with unrecognized or untreated HIV-1 infection. HIV counseling and testing should be offered to all patients before starting Epivir-HBV and periodically during therapy.

CONTRAINDICATIONS:
Previous hypersensitivity reaction to the active component or any of the ingredients

Safety and efficacy of Epivir and Epivir-HBV have not been established in patients younger than 3 months and 2 years, respectively.

Consult WARNINGS section for additional precautions.

Dialysis

Conventional 4-hour hemodialysis and peritoneal dialysis: No additional dose adjustments needed after adjustment for renal dysfunction (based on CrCl); no supplemental dose needed after dialysis.
Prolonged or continuous hemodialysis: Data not available

Other Comments

Administration advice:

• Administer with or without food.
• If patient is unable to swallow a tablet safely and reliably, use the oral solution.
• Only use products appropriate for treatment of HIV-1 in patients with HIV-1 infection; use in combination with other antiretroviral agents.
• Use the formulation and dose recommended for HIV-1 therapy (as part of an appropriate combination regimen) in patients coinfected with HIV-1 and HBV.
• Consult the manufacturer product information regarding missed doses.

Storage requirements:

• Oral solutions: Store in tightly closed bottles at 20C to 25C (68F to 77F).
• Tablets: Store at 25C (77F); excursions permitted to 15C to 30C (59F to 86F).

General:

• Limitations of Use (Epivir): The dosage of this product is for HIV-1 and not HBV.
• The following should be considered when starting therapy with Epivir-HBV:
• Due to high rates of resistance development in treated patients, starting Epivir-HBV should only be considered when use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate.
• Epivir-HBV has not been evaluated in patients coinfected with HIV, HCV, or hepatitis delta virus.
• Epivir-HBV has not been evaluated in liver transplant recipients or in patients with chronic HBV infection with decompensated liver disease.
• During HBV therapy, combinations of events (e.g., persistently elevated ALT recurring, HBV DNA levels increasing over time after initial decline below assay limit, clinical signs/symptoms of hepatic disease progression, and/or hepatic necroinflammatory findings worsen) may indicate loss of therapeutic response; such events should be considered when deciding whether to continue this drug.
• The durability of hepatitis B e antigen (HBeAg) seroconversions occurring during HBV therapy and the relationship between treatment response and long-term outcomes (e.g., hepatocellular carcinoma, decompensated cirrhosis) have not been established.
• The oral solutions contain sucrose; Epivir contains 3 g sucrose per 15-mL dose and Epivir-HBV contains 4 g sucrose per 20-mL dose.

Monitoring:

• Gastrointestinal: For signs/symptoms of pancreatitis in pediatric patients
• General: HIV testing (before starting and periodically during HBV therapy)
• Hepatic: ALT and HBV DNA levels (during HBV therapy); hepatic function of HBV-infected patients with clinical and laboratory follow-up (for at least several months after stopping therapy)

Patient advice:

• Read the US FDA-approved patient labeling (Patient Information).
• Stop this drug if clinical symptoms suggestive of lactic acidosis or pronounced hepatotoxicity develop.
• HBV INFECTION:
• Do not discontinue this product without first informing health care provider.
• Report any new/worsening symptoms to physician without delay.
• HIV-1 INFECTION:
• Discuss any changes in regimen with health care provider.
• Monitor pediatric patients for signs/symptoms of pancreatitis.
• Notify health care provider at once of any signs/symptoms of infection.

Frequently asked questions

• What is the difference between HIV treatments Symfi and Symfi Lo?
• How much does HIV treatment Cimduo cost?
• What drugs are contained in the HIV treatment Delstrigo?
• What drugs are contained in the HIV treatment Cimduo?
• What drugs are contained in the HIV treatment Symfi Lo?

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer